Wisdom Bioscience, Inc., a biotechnology company developing non-invasive oral cancer diagnostics, has announced the formation of its Scientific Advisory Board (SAB) following the completion of its initial funding round. The newly appointed board includes recognized leaders in cell-free DNA research, oncology screening, and molecular diagnostics who will provide strategic scientific and clinical direction as the company advances its product portfolio.
The advisory board includes Drs. Giulia Kennedy, Arnold Levine, John Sninsky, Martin Goldberg, and Professor Tin Tin Su — each bringing extensive experience across genomic diagnostics, oncology research, molecular technologies, and commercialization.
Founded in 2024, Wisdom Bioscience is focused on transforming oral cancer screening by integrating advanced genomic technologies into routine dental visits. Its platform utilizes a simple oral swab combined with next-generation sequencing (NGS) technology to enable early, non-invasive detection of oral cancer.
The company is supported by prominent investors including Stephen Quake and Jay Flatley. Funding will support continued clinical validation and preparation for commercial launch later this year.
Company leadership emphasized that the SAB’s expertise will guide long-term strategy, product development, and commercialization efforts as Wisdom Bioscience moves toward its next funding phase.
